Literature DB >> 2859533

3H-TVX Q 7821: identification of 5-HT1 binding sites as target for a novel putative anxiolytic.

W U Dompert, T Glaser, J Traber.   

Abstract

In order to clarify the mechanism of action of the putative nonbenzodiazepine anxiolytic TVX Q 7821 [2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1, 2-benzisothiazol-3-(2H)one-1,1-dioxidehydrochloride], binding studies with the radio labelled compound were performed. 3H-TVX Q 7821 bound rapidly, reversibly and in a saturable manner with high affinity to calf brain structures with preference for the hippocampus (KD 1.62 nmol/l; Bmax 320 fmol/ mg protein). 3H-TVX Q 7821 binding was displaced only by 5-hydroxytryptamine and its agonists and antagonists including spiperone, but was not displaced by a variety of other neurotransmitters and drugs. The 5-HT2 receptor antagonist ketanserin was a weak displacer. The hippocampal binding sites for 3H-TVX Q 7821 were pharmacologically very similar to the 5-HT1-binding sites in this region. TVX Q 7821 is likely to be an important tool in research on functional aspects of 5-HT1 binding sites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859533     DOI: 10.1007/bf00692918

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  16 in total

1.  Buspirone: action on serotonin receptors in calf hippocampus.

Authors:  T Glaser; J Traber
Journal:  Eur J Pharmacol       Date:  1983-03-18       Impact factor: 4.432

2.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

3.  8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.

Authors:  L E Arvidsson; U Hacksell; J L Nilsson; S Hjorth; A Carlsson; P Lindberg; D Sanchez; H Wikstrom
Journal:  J Med Chem       Date:  1981-08       Impact factor: 7.446

4.  Affinity spectra: a novel way for the evaluation of equilibrium binding experiments.

Authors:  H J Tobler; G Engel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-04       Impact factor: 3.000

5.  Quantitative autoradiography of serotonin receptors in the rat brain.

Authors:  A Biegon; T C Rainbow; B S McEwen
Journal:  Brain Res       Date:  1982-06-24       Impact factor: 3.252

Review 6.  Problems in in vitro receptor binding studies and identification and role of serotonin receptor sites.

Authors:  J Leysen
Journal:  Neuropharmacology       Date:  1984-02       Impact factor: 5.250

7.  Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821.

Authors:  J Traber; M A Davies; W U Dompert; T Glaser; T Schuurman; P R Seidel
Journal:  Brain Res Bull       Date:  1984-06       Impact factor: 4.077

8.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT.

Authors:  H Gozlan; S El Mestikawy; L Pichat; J Glowinski; M Hamon
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

9.  Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain.

Authors:  N W Pedigo; H I Yamamura; D L Nelson
Journal:  J Neurochem       Date:  1981-01       Impact factor: 5.372

10.  Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats.

Authors:  R Samanin; T Mennini; A Ferraris; C Bendotti; F Borsini; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

View more
  36 in total

1.  Species differences in the mechanism through which the serotonergic agonists indorenate and ipsapirone produce their anxiolytic action.

Authors:  A Fernández-Guasti; E Hong; C López-Rubalcava
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

3.  Characterization of an endothelial 5-hydroxytryptamine (5-HT) receptor mediating relaxation of the porcine coronary artery.

Authors:  G J Molderings; G Engel; E Roth; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

4.  Investigations of cardiovascular 5-hydroxytryptamine receptor subtypes in the rat.

Authors:  J R Docherty
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

5.  Evidence for the involvement of the 5-HT1A receptor in the anxiolytic action of indorenate and ipsapirone.

Authors:  A Fernández-Guasti; C López-Rubalcava
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Proceedings of the British Pharmacological Society. Liverpool, 6th-8th April, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

7.  Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.

Authors:  I Berlin; S Chalon; C Payan; G Schöllnhammer; F Cesselin; O Varoquaux; A J Puech
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

8.  8-[3H]hydroxy-2-(di-n-propylamino) tetralin binding sites in goldfish retina.

Authors:  L Lima; C Schmeer; M Urbina
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

9.  Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the rat vena cava.

Authors:  G J Molderings; K Fink; E Schlicker; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

10.  Pharmacological characterization of 5-hydroxytryptamine-induced hyperpolarization of the rat superior cervical ganglion.

Authors:  S J Ireland; C C Jordan
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.